PEPGEN INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
PEPGEN INC. (PEPG) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $11.70 per share for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2022-11-10
- PEPGEN INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $7.50.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month |
|---|---|---|---|
| 2022-09-30 | $11.70 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | $7.82 10-Q · filed 2022-08-12 | ||
| 2022-03-31 | $7.50 10-Q · filed 2022-06-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |